CHMP recommend market authorisation of crizanlizumab (Adakveo)

Crizanlizumab is a monoclonal antibody that binds to P-selectin on endothelial cells and platelets, preventing their interaction with endogenous ligands. It is intended to be licenced for the prevention of recurrent vaso-occlusive crises (VOCs) in sickle cell disease.

European Medicines Agency